Sintilimab

How it works

Benefits

Evidence quality

Highlighted claims

• Sintilimab is an intravenous anti-PD-1 monoclonal antibody used as the immunotherapy component of the trial regimen. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Prior evidence from ORIENT-32 and ORIENT-31 establishes the feasibility and preliminary efficacy of the sintilimab-IBI305 combination in solid tumours, providing a scientific foundation for the triple regimen. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Anti-PD-1 plus chemotherapy has provided inconsistent survival benefit across major gastric cancer trials, particularly in patients with low or absent PD-L1 expression. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Adding sintilimab to bevacizumab and chemotherapy is hypothesised to improve remission rates and prolong survival compared with immunotherapy plus chemotherapy alone, particularly in PD-L1-low or PD-L1-negative patients. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial